β¨ Medicine Consent Notices
21 MARCH
NEW ZEALAND GAZETTE
733
Renewal of Provisional Consent to the Distribution of New Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Arava
Active Ingredient: Leflunomide 10mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Hoechst Marion Roussel, Usiphar Production Unit, Compeigne, France
Note: This consent is valid for 2 years from 23 March 2002.
Product: Arava
Active Ingredient: Leflunomide 20mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Hoechst Marion Roussel, Usiphar Production Unit, Compeigne, France
Note: This consent is valid for 2 years from 23 March 2002.
Product: Arava
Active Ingredient: Leflunomide 100mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Hoechst Marion Roussel, Usiphar Production Unit, Compeigne, France
Note: This consent is valid for 2 years from 23 March 2002.
Product: Gutron
Active Ingredient: Midodrine hydrochloride 2.5mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Nycomed Austria GmbH, Linz, Austria
Note: This consent is valid for 2 years from 30 April 2002.
Product: Gutron
Active Ingredient: Midodrine hydrochloride 5mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Nycomed Austria GmbH, Linz, Austria
Note: This consent is valid for 2 years from 30 April 2002.
Dated this 13th day of March 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go1825
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Chirocaine
Active Ingredient: Levobupivacaine hydrochloride 2.816mg/mL equivalent to 2.5mg/ml levobupivacaine
Dosage Form: Solution for injection
New Zealand Sponsor: Abbott Laboratories (NZ) Limited
Manufacturer: Antigen Pharmaceuticals Limited, Roscrea, Co. Tipperary, Eire
Product: Chirocaine
Active Ingredient: Levobupivacaine hydrochloride 5.633mg/mL equivalent to 5mg/mL levobupivacaine
Dosage Form: Solution for injection
New Zealand Sponsor: Abbott Laboratories (NZ) Limited
Manufacturer: Antigen Pharmaceuticals Limited, Roscrea, Co. Tipperary, Eire
Product: Chirocaine
Active Ingredient: Levobupivacaine hydrochloride 8.449mg/mL equivalent to 7.5mg/mL levobupivacaine
Dosage Form: Solution for injection
New Zealand Sponsor: Abbott Laboratories (NZ) Limited
Manufacturer: Antigen Pharmaceuticals Limited, Roscrea, Co. Tipperary, Eire
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 26
Gazette.govt.nz —
NZ Gazette 2002, No 26
β¨ LLM interpretation of page content
π₯ Renewal of Provisional Consent to the Distribution of New Medicines
π₯ Health & Social Welfare13 March 2002
Medicines, Consent, Arava, Gutron, Aventis Pharma, Douglas Pharmaceuticals
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare13 March 2002
Medicines, Consent, Chirocaine, Abbott Laboratories, Antigen Pharmaceuticals
- G. R. Boyd, Chief Advisor, Safety and Regulation